Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study

This article was originally published here

The randomized controlled trial will enroll approximately 30 patients with Relapsing MS for eight weeks treatment with digital therapy and evaluate dosing, patient use, engagement, and other clinical

The post Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply